(Q43035588)

12 November 2017

title

Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR. (English)

1 reference

12 November 2017

1 reference

Xue-Bing Yan

1

1 reference

12 November 2017

Serena Battaglia

2

1 reference

12 November 2017

Delphine Boucreux

3

1 reference

12 November 2017

Zhi Chen

4

1 reference

12 November 2017

Christian Brechot

5

1 reference

12 November 2017

Nicole Pavio

6

1 reference

12 November 2017

language of work or name

1 reference

30 January 2007

1 reference

12 November 2017

1 reference

12 November 2017

volume

125

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

79-87

1 reference

Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

The natural history of hepatitis C virus (HCV) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

The double-stranded RNA-dependent protein kinase PKR: structure and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Molecular basis for PKR activation by PACT or dsRNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Homotypic interaction and multimerization of hepatitis C virus core protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

PKR: a new name and new roles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Suppression of apoptotic cell death by hepatitis C virus core protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Transcriptional repression of p53 promoter by hepatitis C virus core protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Proapoptotic effect of hepatitis C virus CORE protein in transiently transfected cells is enhanced by nuclear localization and is dependent on PKR activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Interruption of myogenesis by transforming growth factor beta 1 or EGTA inhibits expression and activity of the myogenic-associated (2'-5') oligoadenylate synthetase and PKR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

7 January 2021

Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

7 January 2021

Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

7 January 2021

Biosynthesis and biochemical properties of the hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

7 January 2021

Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

7 January 2021

Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.12.010

7 January 2021

10.1016/J.VIRUSRES.2006.12.010

Identifiers

DOI

1 reference

12 November 2017

1 reference